This text was generated using OCR and may contain errors. Check the original PDF to see the document submitted to the regulator.

Docusign Envelope ID: 6BC1C99D-70B1-8F25-81A3-6EF0709C47F2

Hyperlipidaemia Education & Atherosclerosis Research Trust UK

(A company limited by guarantee)

Registered number: 02631049 Charity number: 1003904

Trustees' report and financial statements for the year ended 28 February 2026

Docusign Envelope ID: 6BC1C99D-70B1-8F25-81A3-6EF0709C47F2

Hyperlipidaemia Education & Atherosclerosis Research Trust UK (trading as HEART UK) (A company limited by guarantee)

Trust UK (trading as HEART UK) (A company limited by guarantee)

Contents
	Page
Reference and administrative details of the charity, its trustees and advisers	1
Impact report	2 - 3
Trustees' report	4 - 19
Independent auditors' report	20 - 23
Consolidated statement of financial activities	24
Consolidated balance sheet	25
Charity balance sheet	26
Consolidated statement of cash flows	27
Notes to the financial statements	28- 42

Docusign Envelope ID: 6BC1C99D-70B1-8F25-81A3-6EF0709C47F2

Hyperlipidaemia Education & Atherosclerosis Research Trust UK (trading as HEART UK) (A company limited by guarantee)

Reference and administrative details of the charity, its trustees and advisers for the year ended 28 February 2026

Trustees

Dr P H Green, Chairman Professor E A Hughes, Trustee Dr D Neely, Trustee Andrew Harrison, Trustee Ms J Bennett, Trustee Dr John Alan Evan Rees, Trustee Mr B A Dobson, Trustee Mr A J Greaves, Trustee Dr D B N Datta, Trustee Mr T M Dixon, Trustee Mr N R Phipps ACA, Trustee (Treasurer) Alison Pottle, Trustee Mr S Handrean, Trustee

Company registered number 02631049

Charity registered number 1003904

Registered office

7 North Road, Maidenhead, Berkshire, SL6 1PE

Company secretary & Chief executive officer

Ms J Payne

Independent auditors

Moore Kingston Smith LLP, 6th Floor, 9 Appold Street, London EC2A 2AP

Docusign Envelope ID: 6BC1C99D-70B1-8F25-81A3-6EF0709C47F2

Our Impact in 2025-2026

Public Awareness and Support

784

people accessed our cholesterol helpline

149,068 publications were distributed to patients with high cholesterol

35,612 people viewed our video resources on YouTube

----- Start of picture text -----
+86%
86%
----- End of picture text -----

said helpine was ‘very easy’ or ‘easy’ to access

23,877 digital materials were downloaded

4,766,560 of you viewed our Facebook posts

146,274

people subscribed to our e-news

----- Start of picture text -----
A 33% increase on the previous year
----- End of picture text -----

----- Start of picture text -----
99.4%
99.7%
----- End of picture text -----

rated our literature at ‘Invaluable’ or ‘very helpful’.

314,876 of you viewed our Instagram posts

2.5m

million people accessed the HEART UK website

2,193 resources for children and young people were downloaded

386,140 viewed our LinkedIn posts

Healthcare Professionals

4,844

HCP’s subscribed to our e-news An 8% increase on the previous year

----- Start of picture text -----
98.6%
----- End of picture text -----

98.6%

of HCPs give our booklets to patients during their consultations

247

HCPs attended our 37th Annual Medical and Scientific Conference ‘National and international perspectives’

25,369 users on our four diet quizzes

768

HCPs attended or viewed our educational webinars

34,203 subscribed to our Cholesterol SMART e-news

----- Start of picture text -----
4.15/5
----- End of picture text -----

HCPs who attended our webinars rated their increase in confidence from 3.21 to 4.15 out of 5 in treating their patients for high cholesterol

96%

of HCPs viewing our Diet & Lipid Network webinars found them useful

HEART UK – actively supported by gifts in wills and donations

www.heartuk.org.uk/about-us/our-impact

Docusign Envelope ID: 6BC1C99D-70B1-8F25-81A3-6EF0709C47F2

National Level Impact

y - Our Key ges Public Affairs and Advocac Messa

Stronger prevention strategies targeting raised cholesterol and its treatment are needed across all four nations of the UK.
All areas of the UK should have access to connected digital workflows to support documentation and appropriate sharing of family pedigrees for familial hypercholesterolaemia (FH).
The HEART UK Lipoprotein(a) Lp(a) Consensus Statement should be adopted, including Lp(a) guideline inclusion and routine testing in clinical practice.

NHS 10 Year Plan: Cardiovascular Disease (CVD) Modern Service Framework (MSF)

Following the publication of the NHS 10 Year Plan (July 2025), HEART UK has been actively consulted on the forthcoming CVD MSF through the MSF Task and Finish Group. We have championed the inclusion of cholesterol and other blood fats as critical CVD risk factors via national groups, including the CVD Prevention Strategic Leadership Group, the National CVD Prevention Expert Advisory Group, and the Cholesterol Working Group.

The Breadth of Our Advocacy work

Convened a dietary roundtable on plant stanols and sterols and continued engagement with NICE to support improvements to clinical guidance.
Worked with the NHS App team to improve digital access to HEART UK patient information.
Maintained dialogue with the Ministry of Defence regarding eligibility of individuals diagnosed with FH to join the Armed Forces.
Collaborated with parliamentary champions to scrutinise government policy and raise awareness of cholesterol as a major CVD risk factor.
Engaged clinicians and patient advocates to strengthen stakeholder influence.
Representing the patient voice, HEART UK ChangeMakers significantly influenced across the healthcare system, NICE and the political environments.
Through the Lp(a) Taskforce, submitted an application to NICE for Lp(a) to be considered as a new topic.
Joined the Genetic Alliance, contributing to Rare Disease Day activities and the Equity for Rare report.
Submitted responses to NICE consultations, including technology appraisals for new medicines, supported by leading HEART UK clinical experts.
Held parliamentary events to launch NHS Frontline Survey findings and to explore digital workflows for FH cascade testing.
Continued bi monthly Integrated Care System (ICS) Champion network calls, supporting local leadership on cholesterol and blood fat priorities.

Publications and Data

PASS: A digital solution to strengthen cascade testing for FH – recommendations demonstrating how digital workflows can support national CVD prevention ambitions.
Cholesterol: The Heart of Prevention – a CVD Collaborative briefing highlighting NHS frontline insights and recommendations for the CVD MSF.
Ongoing use of CVDPREVENT and other datasets to track progress in the diagnosis and treatment of FH across England.

HEART UK – actively supported by gifts in wills and donations

www.heartuk.org.uk/about-us/our-impact

Docusign Envelope ID: 6BC1C99D-70B1-8F25-81A3-6EF0709C47F2

Annual report incorporating a Directors’ Report and Accounts for the year ended 28 February 2026

OBJECTIVES AND ACTIVITIES

Introduction

HEART UK is the UK’s only charity focussed on cholesterol and lipids, lipids being a medical term meaning ‘blood fat’, and whilst there are numerous blood fats, cholesterol is the most common. For this reason, we will refer in this report to just cholesterol but assume this means all blood fats.

In 2002 two charities merged to form HEART UK. The British Hyperlipidaemia Association, a health care professional focused organisation and the Family Heart Association, a patient focused organisation. HEART is an acronym and stands for:

H yperlipidaemia E ducation and A therosclerosis R esearch T rust.

As a result of this merger, HEART UK serves patients, their families and health care professionals, in addition to the general public who may not be aware they have a cholesterol issue.

Almost half of UK adults have raised cholesterol, putting them at an increased risk of heart attacks, strokes and vascular dementia. Raised cholesterol is the most common modifiable risk factor for cardiovascular disease and it can affect anyone, even the young and otherwise healthy. Cholesterol is also the third biggest risk factor for dementia.

Heart and Circulatory diseases cause around a quarter of all deaths in the UK. This means 1 person dies every 3 minutes. More than 8 million people are living with heart and circulatory diseases in the UK, but a lot of this can be prevented.

Inherited cholesterol conditions affect a high number of people across the UK. This means when a child is born and they have an inherited cholesterol condition, they have already had this for 9 months. Children can be at risk and an example of this is around 1 in 250 people (that equates to over 270,000 people across the UK) have the genetic condition familial hypercholesterolaemia (FH), which leads to high cholesterol and an increased risk of heart disease at a young age and even heart attacks in childhood. Currently, only around 10 - 11% of those with FH have been diagnosed in the UK. Millions of people with raised cholesterol caused by other factors are similarly unaware of the risk they face.

Another blood fat, known as Lipoprotein (a) (LP(a) for short), affects around 1 in 5 people. But this is a little known condition by the public and also healthcare professionals, especially those working in primary care.

HEART UK is a registered charity and a company limited by guarantee. We also have a trading subsidiary, HEART UK Trading Company Limited through which the majority of our corporate activity is conducted. The charity’s objects as set out in our constitution are:

‘To relieve those suffering the effects of heart disease and in particular lipid disorders, familial hyperlipidaemias and related conditions, to promote the relief of sickness and the preservation and protection of health by reducing the incidence of vascular disease in the general population of the United Kingdom, to provide counselling and advice to relatives of

Docusign Envelope ID: 6BC1C99D-70B1-8F25-81A3-6EF0709C47F2

those diagnosed with inherited heart disease and to promote the study of causes, diagnosis and treatment of lipid disorders and associated metabolic diseases.’

Aims and objectives

HEART UK provides specialist information, support and expertise to individuals, families and health care professionals working to improve the services available to those who live with high cholesterol. Our single focus means we have been able to build a highly influential and collaborative model, bringing specific patient experience and scientific information together to create effective patient communications and influence Government and public policy. Our focus is entirely on helping people know and understand their cholesterol levels and take appropriate action. We believe that investing our limited resources on this one intervention is the most impactful way of tackling premature cardiovascular disease, disabilities, illness and avoidable early deaths.

We aim to prevent people developing heart disease and dying from avoidable heart attacks, strokes and other conditions that high cholesterol can cause.

Volunteers

Volunteers form a vital part of HEART UK’s activities. We continue to benefit from a range of volunteers including healthcare professionals serving on our committees who willingly give up their time to enable us to be the lead voice on cholesterol and shape the way cholesterol is diagnosed and managed around the UK.

We are also very lucky to be supported by our ambassadors who are the voice of HEART UK in their community; and our ChangeMakers who are using the HEART UK messages and their own voice within their local health system to be a critical friend to improve outcomes for patients with high cholesterol. They help raise awareness of the dangers of cholesterol. We also benefit from a lot of support from dedicated fundraisers helping to raise funds and awareness for our essential work.

Following a successful grant application with the National Lottery we are developing a programme of community service volunteers supported by comprehensive resources to widen our reach and to reduce health inequalities.

The Trustees wish to extend their sincere thanks to all the volunteers who support HEART UK.

Public Benefit

In reporting on the objectives and achievements of the charity, the Trustees have given due regard to the Charity Commission guidance on public benefit under the Charities Act 2022. HEART UK constitutes a public benefit entity as defined by FRS102.

Diversity, equality and inclusion

We have a Diversity policy in place. We are committed to ensuring that the values of equality, diversity and respect are embedded into everything we do. Anyone within the UK can access our services.

Docusign Envelope ID: 6BC1C99D-70B1-8F25-81A3-6EF0709C47F2

Our Values

We operate everything we do within the values of the organisation with professionalism, respect, integrity, empathy and trust.

Environment, Social and Governance

We have developed an Environment, Social and Governance (ESG) action plan and are working to those actions. We continue to work on ensuring ESG is built into our work across the organisation.

We continue to encourage people with the technology to access our information using their mobile phones. In particular, we provide a large amount of literature to the NHS and other organisations. We introduced a sheet of QR codes providing digital access to our literature. which is accessed via a smart phone. Of course, not everyone is in that position, so we still provide printed copies as appropriate. It is important to us that anyone wanting to access our services is able to, no matter their background or where they live.

The Charity Governance Code

We aim to abide by the Charity Governance Code.

ACHIEVEMENTS AND PERFORMANCE

At the beginning of this report is a record of our impact for the year. However, we go into a little more detail below.

Background information

We work closely with lipidologists, scientists, doctors, nurses, pharmacists, dietitians and other healthcare professionals across the NHS, plus food companies, medicine manufacturers and across government bodies such as the Department of Health and Social Care to ensure patients are provided with the information and support they need to manage cholesterol and live a longer, healthier life.

Our main focus is on lowering cholesterol and saving lives via raising awareness with the public, service delivery and educating healthcare professionals and the public, patients, and their families. However, we also work to advocate with and on behalf of people with high and inherited cholesterol conditions, effecting crucial change in policy and standards.

On 3 July 2025 in England, the Government published their NHS 10-year plan. The plan sets out how the NHS and the Government have committed to reducing CVD rates by 25% in the next 10 years. Cholesterol is an important risk factor to be addressed to help this target to be achieved. However, the implementation component was missing from the plan and, as we write this report, we await a new CVD Modern Service Framework (CVD MSF), which we hope will include a set of tangible goals and deliverables to address CVD prevention and treatment. HEART UK have been engaged through the development of this. We expect this to be published mid-late May 2026.

During this year we have invested in further developing our team and also our Cholesterol SMART Programme, which we discuss later in this report.

Over the coming years we will continue to build on our successes, ensuring that this target and others to come are delivered

Docusign Envelope ID: 6BC1C99D-70B1-8F25-81A3-6EF0709C47F2

The team

During 2025/26 the incredible HEART UK team continued to work hard to deliver our objectives and support our beneficiaries. We have invested in our Fundraising Team and also in our Service delivery, in particular our dietetic services. We also investing in the team by appointing a new Head of External Affairs to lead on all our policy and public affairs activities. The impact report demonstrates the real impact of our amazing team, which include our internal team, consultants and of course volunteers.

Providing scientifically based, factually accurate information

We provide a range of information both on and offline covering each of the conditions we support. All our information is scientifically based and factually accurate.

For people who have been identified as at risk of or having an inherited cholesterol condition, knowledge and information is varied within primary care, including GPs and pharmacists, who may be unfamiliar with the condition and referrals to specialist lipidology consultants can involve very long waiting times. This can be a very anxious time for patients and their families, which is not helped by a plethora of confusing and contradictory information available online.

HEART UK addresses this issue by working with GP Surgeries, pharmacists and clinics across the country to offer patients user-friendly, evidence-based and practical information and advice on how to understand and tackle high cholesterol. We also have a number on free online learning modules available for healthcare professionals.

All our information and support is produced by our lipid specialist nurse and dietetic advisor who are supported by our Medical, Scientific and Research and Healthcare Committee members. This information and advice is regularly updated.

The most popular leaflets include ‘Understanding Cholesterol’, “blood fats explained and ‘Healthy Eating’, but we also provide information specifically for certain groups, such as children with FH. We have booklets aimed at children of different ages living with FH to help them understand their condition.

We aim to ensure that patients who have been diagnosed with high cholesterol have access to quality information to explain and support them. We monitor the uptake and re-orders of literature by healthcare professionals. We provide the majority of our literature free of charge. We know that our literature provision does increase access to quality information. Enquirers to our Helpline frequently report they received our literature via their GP and are getting in touch as they have further questions – demonstrating both that the need for information exists and that HEART UK’s services are helping to address this need. We also recognise the need to offer digital versions of our literature and we have developed options for digital access which has grown in popularity this year. I parallel we have been looking at ways to reduce print and postage costs without affecting the quality or accessibility of our literature. We are also looking to widen our resources to include translated versions and to support other health literacy requirements.

The HEART UK Helpline

Our dedicated helpline offers information and support on email and over the phone. The helpline responds to a clear need for support in dealing with a variety of queries relating to cholesterol or concerns about family history of heart disease. Obtaining GP appointments, limited time and information available from GPs, waiting lists for lipid specialists and a profusion of misinformation on the internet all contribute to a situation where people lack accurate information. People who are worried about raised cholesterol or are not sure what to do about their levels, often have nowhere

Docusign Envelope ID: 6BC1C99D-70B1-8F25-81A3-6EF0709C47F2

to turn to for support and end up doing nothing – or worse, relying on inaccurate advice and information from the internet which can endanger their health.

The HEART UK Helpline is uniquely run by our expert lipid specialist nurse and specialist dietetic advisor, supporting anyone that contacts us to help them manage their cholesterol and other blood fats. The Helpline also supports people diagnosed with, or who are bereaved of someone with an inherited high cholesterol condition. These enquiries can be complex and require expert knowledge and professional handling and are often ‘time heavy’. Once again, during this year we have continued to see people enquiring about LP(a).

Our Services team of specialists provide the information and advice in our literature, on our website, in our social media posts and take part in conferences and webinars, radio broadcasts and other PR activities designed to raise awareness of the dangers of high cholesterol and the steps individuals can take to manage it.

Our Helpline users tell us how important our service is to them and often support our advocacy and fundraising.

Healthcare professional support

Support for healthcare professionals over 2025/26

We continue to provide a large amount of literature to healthcare professionals free of charge to distribute to their patients. We are looking at ways we can balance the requirement to a mutually beneficial mix of digital and hard copy information and will progress this into 2026/2027.

We continued to deliver many education activities for healthcare professionals through our ‘Tackling Cholesterol Together’ campaign.

Lipid Intelligence Network

This network provides a source of network support through our regular monthly teams calls to bring together healthcare professionals dealing with cholesterol conditions where discussion take place around challenges, sharing information, best practice, and learn from each other. We are seeing a more varied range of professionals who enjoy the support this network provides.

Lipid Interest Group

This is a group of 160 allied health professionals, from FH and apheresis nurses to GP practice nurses, who meet twice a year to network and share information. Once a month they circulate a ‘round robin’ featuring a recent example of their work. This proves useful to all.

Other networks

Our networks continue to evolve:

Early career CVD prevention network
The UK Paediatric FH Alliance
The Diet and Lipid Network

Docusign Envelope ID: 6BC1C99D-70B1-8F25-81A3-6EF0709C47F2

Annual scientific conference

In 2025 we held a hybrid annual scientific conference. Total attendance was 359, an increase from 2024. 78% in person and 22% virtual. The attendance by profession trend was the same as 2024.

Just under 98% of the attendees surveyed said they would be able to apply the learnings in their day-to-day practice to improve patient outcomes.

Nutrition Academy

Our Nutrition Academy is an online platform aimed at providing information and training to all healthcare professionals who deliver dietary advice to individuals diagnosed with high cholesterol. We have recognised the lack of dietetic support in specialist areas, and the challenges in accessing these services in other areas. This has led to non-dietetically trained staff feeling responsible for advising patients.

The purpose is to provide an online centre of excellence to ensure healthcare professionals can provide accurate, evidence-based information to their patients on how to manage their condition to reduce their risk of cardiovascular disease. An advisory panel of experts in the field of nutrition and dietetics helps us steer the programme. Once again, this is proving extremely popular because there is a severe lack of dietetic support within the NHS. To support the web platform, a quarterly Nutrition Academy e-newsletter has been launched to provide healthcare professionals with the latest research, news and expert views to stay abreast of the dietary management of cholesterol.

HEART UK developed a quick dietary guide to help healthcare professionals conduct rapid assessments of patients’ diets and provide tailored dietary advice based on their responses. A survey is currently underway to evaluate changes in healthcare professionals’ confidence and their likelihood of providing dietary advice for cholesterol management after using the guide. The results are expected to be submitted for publication in a scientific or medical journal in 2026/2027.

Major Achievements

ChangeMaker Programme

Representing the patient voice, our three ChangeMakers have significantly influenced across the healthcare system, National Institute for Health and Care Excellence and the political environments.

Emerging opportunities include:

The development of ‘specialist’ national ChangeMaker roles based on their existing interests and strengths.
Genetic forms of hyperlipidaemia
Paediatric to Adult services transition
Women’s Health
South Asian communities
National policy and strategy

They can also provide support and resource for:

Awareness building with the introduction of HEART UK service volunteers
The development of a strategy for the introduction of ChangeMaker in Scotland.

Docusign Envelope ID: 6BC1C99D-70B1-8F25-81A3-6EF0709C47F2

Policy and public affairs

During 2025/26 , HEART UK has had much to celebrate with our public affairs activities. Responding to consultations, in particular around the CVD MSF and also with NICE and their reviews of guidelines and treatments.

We continued to hold our Integrated Care System (the payers of the health system) network calls bimonthly. This is very successful bringing system leaders together to share information and best practice and to learn from each other and also to understand developments and the focus in other areas.

We have been making significant efforts since 2016 to get FH identified as early as possible. HEART UK is the only charity championing this since it was proven to be so successful in a research study of 10,095 children which was published in 2016. We believe screening children for FH should be a national screening programme. Testing children early will lead to whole family screening. A twoyear pilot was established and the results of this were published which set out the challenges and considerations in order to introduce such a screening programme. The importance of this being accepted by an organisation known as the UK National Screening Committee is that, if successful, the screening will be across the whole of the UK. We continue to engage with the UK NSC.

Genomics England continue with their pilot research project in England for new-born screening and Homozygous FH and Familial chylomicronaemia syndrome (FCS) are included. This will be important in the process with the UK National Screening Committee. However, they are only testing 100,000 babies and these two conditions are so rare there is a risk they will not identify any. We await the results of this pilot, depending on the results, this could lead to these conditions being included in a new blood test for newborn babies.

We continue to campaign for a digital workflow system for FH (PASS) which connects FH services and supports coordinated cascade testing across families and regions. We held a parliamentary roundtable, developed a recommendations paper, distributed the paper to key stakeholders (including Ministers and senior civil servants) and engaged on the issue with stakeholders ahead of the publication of the CVD MSF.

Through the CVD Collaborative, we have started using our advocacy branding ‘Cholesterol: The Heart of Prevention.’ This has included publishing the results of an NHS Frontline survey and launching them at a parliamentary drop-in. We have used the survey results to articulate our key ambitions for the CVD MSF, and engage key stakeholders. Our political engagement is working well, including a meeting programme, suggested parliamentary questions being tabled in both the Lords and the Commons, and correspondence with Ministers and others.

Cholesterol SMART

Having launched our Cholesterol SMART programme in 2025/26, we produced a scientific dossier to demonstrate the science behind the programme. This has been well received by key stakeholders. Part of this programme includes a quarterly Cholesterol SMART e-newsletter being distributed, with subscriber numbers continuing to grow.

As a result of engagement with NICE, our Cholesterol SMART programme is now included in NHS Futures, a private professional network specifically for health and care staff to collaborate, connect and share information. Cholesterol SMART has been signposted as a resource to support the implementation of NG238 (Cardiovascular disease: risk assessment and reduction, including lipid modification).

Docusign Envelope ID: 6BC1C99D-70B1-8F25-81A3-6EF0709C47F2

Awareness raising

We are constantly raising awareness of the dangers of cholesterol and the need for people to take their cardiovascular risk seriously as early as possible. We have great success with this across all our communication channels.

We have delivered a number of public information events in 2025/2026 and look to continue and increase these over the coming year. The feedback to date has been impressive.

PRINCIPLE FUNDING

HEART UK’s approach to fundraising is relationship led, via a variety of income streams:

Individual giving – regular and single gifts, appeals, in memory and payroll giving, and weekly lottery
Digital fundraising including online auction, recycling schemes and e-cards
Sporting challenges - including the London Marathon and a wide variety of challenge events
Legacies and an annual free Will campaign
Corporate partnerships, including food, gyms, clothes recycling, solicitors, diagnostics and pharmaceutical companies
Trusts and Foundations
Employee Wellbeing Programme on cholesterol

During this period, HEART UK have been humbled to receive a number of legacies:

Deceased legator	Receivable in 2025/26
JCC	141,749
DAC	122,672
VJT	179,861
GAJC	39,090
SJM	2,700
Total	486,071

We are extremely grateful for any donation to us, no matter how small. Leaving a legacy to HEART UK is the final compliment anyone can make. Whilst we received some funds in this financial year, some of these funds are restricted for particular projects in 2026/27.

HEART UK has a commercial relationship with our food partners whereby a company will apply to use our product approval logo on their products. These applications are assessed by our expert Product Approval Task and Finish Group against a stringent process and very strict criteria. We also have commercial participator relationships with companies with whom we have entered in a partnership. HEART UK does not carry out street collections or house-to-house fundraising, other than sticker drops by one of our clothes recycling partners. HEART UK has a Safeguarding and child/vulnerable adults protection policy in place. The Board of Trustees set up a subgroup to create

Docusign Envelope ID: 6BC1C99D-70B1-8F25-81A3-6EF0709C47F2

and review policies and all other Board members are kept up to date with the changes and are required to familiarise themselves with each policy. The staff are required to familiarise themselves with all of our policies each year and are provided with appropriate training.

HEART UK is registered with the Fundraising Regulator and adhere to the Code of Fundraising Practice. HEART UK complies with the Charities Act and GDPR regulation. We put the privacy of our supporter data at the heart of everything we do. We manage personal data respectfully and responsibly in accordance with our published privacy policy.

We have a register of vulnerable people which is regularly reviewed by our Chief Executive.

We established a complaints register in 2017/18 and have received 239 complaints between 2017/18 and 2025/26. These have largely been about clothes recycling and have decreased over those years as we work with our clothes recycling partners to learn from feedback and improve processes. In 2025/26, HEART UK received one complaint. This is a very low figure for the sector. Nevertheless, as mentioned earlier, we are committed to studying any expression of dissatisfaction and identifying ways to improve. The appropriate team investigate each complaint. Our complaints procedure is publicly available on our website.

Without the support of our donors and fundraisers, we would not be able to operate, and we are incredibly grateful for every penny that is donated or raised, helping us to save lives and keep families together.

RISK MANAGEMENT

The Trustees have assessed the major risks to which HEART UK is exposed and are satisfied that systems are established to mitigate the charity’s exposure to those risks. These risks are detailed on a risk register, reviewed quarterly by our Finance and Risk Committee and annually by our Board of Trustees.

The biggest risks currently featuring on our register are:

Cyber fraud. Many charities are experiencing cyber fraud. We consider we have robust procedures in place to best avoid this and have developed a specific cyber fraud policy.
Funding. We regularly review the funding situation via quarterly Finance and Risk Committee meetings, plus an additional meeting in between to keep a close look on matters.
Reliance on individuals. We are focusing on retaining staff as well as recruiting good people to the team.

FINANCIAL REVIEW

Income for the year ended 28 February 2026 totalled £1,894,907 (£1,577,004 in 2024/25)

Expenditure on raising funds was £764,699 (£719,130 in 2024/25) and charitable activity spending was £810,962 (£773,917 in 2024/25).

Of particular note:

The clothes collections remained strong in particular through our partnership with iCollect Clothes.

Docusign Envelope ID: 6BC1C99D-70B1-8F25-81A3-6EF0709C47F2

INVESTMENT POLICY

Under the Memorandum and Articles of Association, the charity has the power to invest in any way the Trustees see fit.

The policy of the charity is to adopt a low-risk strategy at present. We have one investment which is low risk with no investment in tobacco, alcohol or arms.

RESERVES POLICY

The reserves policy is set by the Board of Trustees and reviewed annually. We aim to hold free reserves in the range of 6 – 9 months’ worth of operating expenditure. Our free reserves at the year-end totalled £855,043 which is within our 6-9 month guideline and we expect this to be maintained throughout the next 12 months.

PLANS FOR THE FUTURE

Our vision is to: Prevent early disease and deaths from cholesterol and other blood fat (lipid) conditions in the UK.

We aim:

To increase the number of people identified in the UK with inherited lipid conditions from 25,000 to 50,000 by 2029.
For people to know and understand their cholesterol and other blood fat (lipid) levels and take appropriate action.

We are working to a 10-point strategy plan to 2029:

During 2026/27 we will:

Continue with our Cholesterol Helpline ensuring we provide the best ways for people to get in touch with us.
Regularly review our information provided to ensure it is up to date.
Continue to review the provision of our literature orders to ensure efficiencies and cost effectiveness where possible. We will also consider the environment in this process.
Build on our education provision for all beneficiaries.

Docusign Envelope ID: 6BC1C99D-70B1-8F25-81A3-6EF0709C47F2

Continue to build our communication channels to further increase our reach and influence, ensuring we reach as many people for all ranges of backgrounds.
Publish appropriate expert papers in order to ensure best practice treatment and management of lipid patients.
Launch the HEART UK Research Grant Scheme, in particular to encourage early career specialist development..
Continue to ensure heart and circulatory disease is a key priority for the Government and NHS.
The inconsistent reporting on cholesterol levels, needs to be changed and we will be working towards achieving standarised reporting, following the recent publication.
Incentives are important within the health system. In England, the Quality and Outcomes Framework (QOF) incentivises lipid management as part of secondary prevention (post heart attack or stroke and established heart disease). However, these incentives could be more ambitious, and we will be working to advocate for higher QOF thresholds to maximise patient outcomes. We will also continue our work on primary prevention through our engagement with stakeholders and our public health messaging.
Work in the devolved nations to ensure cholesterol conditions are given priority and an action plan to improve patient outcomes. This includes our plans to establish a CVD Collaborative Scotland.
We will advocate for improvements in NICE Guidelines to bring them more in line with European standards, and a higher treating to target ambition.
We will continue our campaign for FH to be included in infant screening, with a new Health Economics Report intended to provide compelling evidence for this initiative, which we will submit to the UK National Screening Committee.
Continue to lobby for FH to be identified as early as possible; in children and adults.
Continue to engage on other inherited forms of lipids.
Continue to work to get the LP(a) calls to action adopted and implemented
Continue to lobby for data to be captured to ensure we know exactly what the picture looks like with cholesterol patients both locally and nationally, this will include improved cholesterol and FH reporting through CVDPrevent.
Continue with our ChangeMaker Programme and add to our offering with more volunteers.
Build our reach and regional presence
Continue to grow Cholesterol SMART with practical assets to support the programme
Launch a new Cholesterol SMART recipe subscription – Cholesterol SMART Living- which will provide another income source for HEART UK.

During 2026/27 we will have a change of Chief Executive. We have had a long serving Chief Executive with Jules Payne serving 16 years. We are working on a carefully curated appointment and transition.

STRUCTURE, GOVERNANCE AND MANAGEMENT

The charity is governed by a Board of Trustees who are legal members and also directors of the charity for the purposes of the Companies Act. The Board sets the strategic direction of the charity ensuring that the charitable purposes are met. The Board of Trustees delegate the day to day running of the charity to the Chief Executive.

HEART UK considers each of the Trustees to be independent in character and judgement; and understands that they have no relationships that are likely to affect, or could appear to affect, their judgements with regard to HEART UK. Declarations of interest are required from new Trustees upon appointment, annually and every meeting of the Board requires that any new interests are

Docusign Envelope ID: 6BC1C99D-70B1-8F25-81A3-6EF0709C47F2

declared. No remuneration is provided except for reasonable travel and subsistence costs. These costs totalled £0 during 2025/26 (£0 in 2024/25). The trustees made no claims for expenses.

During 2025/26 we had no Trustee resign from the Board of Trustees. Dr Alan Rees stood down as our Medical Director, and we would like to thank him for all his support and work in this role over many years. Professor Elizabeth Hughes has been appointed as our new Medical Director.

There are a number of committees and task and finish groups that serve the Board of Trustees to assist in the delivery of our objectives:

Committees

Finance and Risk

Key areas for this committee are:

To be responsible for financial and general business affairs of the charity including:
Risk Management
Financial Control Management
Audit and presenting final accounts to the AGM following Board approval.
Reviewing annual accounts prior to Board and then AGM approval.

Income, Communications and Services

Key areas for this committee are:

To oversee the services we deliver
To oversee our communications and channels used
To oversee our income generating and fundraising activities

Medical and Scientific Research Committee (MS&R)

Oversees the Annual Conference, the development of research and speciality training programmes, clinical guidelines development and creating and updating our information.

The Healthcare Committee

Key areas of interest:

Provides up-to-date information to health care professionals who care for patients and their families with lipid disorders.
They co-organise the Health Care part of the Annual Conference.

Policy and Public Affairs Committee

The Committee sets and oversees the implementation of HEART UK’s strategy for influencing and shaping the external environment to achieve the charity’s objectives. The Committee’s focus will be primarily, but not exclusively, on Government and NHS policy and practices.

Docusign Envelope ID: 6BC1C99D-70B1-8F25-81A3-6EF0709C47F2

Board Nomination Committee

The Committee reviews the composition of the Board of Trustees, oversees the recruitment of any new Trustees, Chair and also the Chief Executive role. However, responsibility for decision-making lies with the Board, which retains ultimate responsibility for running the Charity in accordance with its Articles of Association and the guidance provided by the Charity Commission.

Task and finish groups

These groups meet when there is a task to be actioned:

Lipoprotein Apheresis

Key areas of interest:

To promulgate guidance for the clinical indication for lipoprotein apheresis.
To review and recommend the criteria of efficacy of performance in the UK (Assessment to be based on Registry data jointly formed by HEART UK).
To educate society in general about Apheresis as a treatment.

Conference organising

This group organises the annual scientific conference usually held in June or July over a 3-day period.

Research Grant Scheme

This group will be overseeing our grant-giving scheme, review applications and award grants.

Policy Development

Operates to develop, oversee and review the policies of the organisation.

Product Approval

For approved commercial products that bear the HEART UK logo. The group operates within an ethical and scientific policy framework to evaluate products for approval.

Cardiovascular Disease Collaborative

This group meet to drive forward particular campaigns around changing health policy for the NHS and Government.

ChangeMaker

This group oversees the programme and steers the direction of travel.

Community Service Volunteers

This group oversees the programme and steers the direction of travel for the development of the community toolkit

The Simon Broome Steering Committee

Is responsible for directing research based on a national cohort of over 3,500 patients with familial hypercholesterolaemia (and severe hypertriglyceridemia).

Docusign Envelope ID: 6BC1C99D-70B1-8F25-81A3-6EF0709C47F2

STAFF

A Senior Leadership team, consisting of the Chief Executive and Heads of Fundraising, Services and External Affairs allows for the distribution of organisational responsibility. The Chief Executive has particular responsibility for issues relating to governance and for the financial management of the organisation.

HEART UK has 9 permanent members of staff, 4 full time and 5 part time.

The Trustees would like to record their appreciation of the efforts of the staff, who have again made an enormous contribution to the successes of HEART UK during the year.

PAY AND REMUNERATION

The Finance and Risk Committee review the salaries of the staff and advise the Board on any recommended changes. This is dictated by market forces and affordability. We also review our pay scale to focus on retention and also attract excellent talent.

The remuneration of the Chief Executive is assessed by the Board of Trustees. This includes conducting a 360-degree assessment when appropriate; internally and externally, market forces, performance and affordability.

AUDITOR

The auditors of the charity and trading company are reviewed by our Board of Trustees and appointed as appropriate at our Annual General Meeting.

TRUSTEE APPOINTMENT, INDUCTION AND TRAINING

Trustees are appointed in accordance with HEART UK’s constitution, taking into account the benefits of appointing a person who is able, by virtue of their personal or professional qualifications, to make a contribution to the pursuit of the objects or the management of the charity.

Trustees consider the skills gap on the Board of Trustees. Trustee vacancies are openly advertised and recruited following an interview and selection process and then proposed and appointed at the AGM.

HEART UK undertakes an induction programme for all new trustees, including induction materials relating to its purpose and finances, the powers of trustees and information about the day to day running of the organisation. Key documents are provided, such as the constitution, accounts, minutes of recent meetings and policies.

Trustees continue to be supported through ongoing training.

SMALL COMPANIES REGIME

This report has been prepared in accordance with the special provisions relating to small companies within Part 15 of the Companies Act 2006.

CONSIDERATION OF GOING CONCERN

The company continues to adopt the going concern basis in preparing its financial statements.

The trustees have assessed whether the use of the going concern basis is appropriate and have considered possible events or conditions that might cast significant doubt on the ability of the

Docusign Envelope ID: 6BC1C99D-70B1-8F25-81A3-6EF0709C47F2

company to continue as a going concern. The trustees have made this assessment for a period of at least one year from the date of approval of the financial statements. In particular, the trustees have considered the company's forecasts and projections. As part of the going concern review the trustees prepared a detailed, forward-looking cash flow scenario, based on the most realistic assumptions available at the time. In this scenario the company had adequate resources to continue in operation for at least twelve months from the approval of the financial statements.

STATEMENT OF TRUSTEES’ RESPONSIBILITIES

The Trustees (who are also directors of company for the purpose of company law) are responsible for preparing the trustees’ report and the financial statements in accordance with applicable law and United Kingdom Accounting Standards (United Kingdom Generally Accepted Accounting Practice).

Company law requires the Trustees to prepare financial statements for each financial year which give a true and fair view of the state of affairs of the charitable company and the group and of the incoming resources, including the income and expenditure of the charitable group for that period. In preparing these financial statements, the Trustees are required to:

select suitable accounting policies and then apply them consistently;
make judgments and estimates that are reasonable and prudent;
state whether applicable UK Accounting Standards have been followed, subject to any material departures disclosed and explained in the financial statements;
prepare the financial statements on the going concern basis unless it is inappropriate to presume that the charity will continue in business; and
observe the methods and principles in the Charities SORP.

The Trustees are responsible for keeping proper accounting records that disclose with reasonable accuracy at any time the financial position of the charitable company and enable them to ensure that the financial statements comply with the Companies Act 2006. They are also responsible for safeguarding the assets of the charitable company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

AUDIT INFORMATION

So far as each of the Trustees at the time the Trustees' report is approved is aware:

there is no relevant information of which the auditors are unaware; and
they have taken all relevant steps they ought to have taken to make themselves aware of any relevant audit information and to establish that the auditors are aware of that information.

AUDITORS

A resolution for the appointment of auditors will be put to the forthcoming AGM.

Docusign Envelope ID: 6BC1C99D-70B1-8F25-81A3-6EF0709C47F2

THANKS FROM THE CHAIR OF TRUSTEES

I would like to extend my personal and sincere thanks to our dedicated and highly committed and capable team at HEART UK, to my Board of Trustees, our Committee members, ChangeMakers, Ambassadors and volunteers who continue to give their valuable time, commitment and amazing contributions to help HEART UK truly deliver a world class service for our beneficiaries.

14/8/2026 Authorised by the Trustees on ………………………………….. and signed on their behalf by: Dr Peter Green, Chair

Docusign Envelope ID: 6BC1C99D-70B1-8F25-81A3-6EF0709C47F2 Hyperlipidaemia Education & Atherosclerosis Research Trust UK (trading as HEART UK) (A company limited by guarantee)

Independent Auditors' Report to the trustees of HEART UK

Opinion

We have audited the financial statements of Hyperlipidaemia Education & Atherosclerosis Research Trust UK (the 'company') for the year ended 28 February 2026 which comprise the Consolidated Statement of Financial Activities, the Group and Parent Charitable Company Balance Sheets, the Consolidated Statement of Cash Flows and notes to the financial statements, including a summary of significant accounting policies. The financial reporting framework that has been applied in their preparation is applicable law and United Kingdom Accounting Standards (United Kingdom Generally Accepted Accounting Practice) including FRS 102 "The Financial Reporting Standard Applicable in the UK and Ireland".

In our opinion the financial statements:

give a true and fair view of the state of the group’s and the parent charitable company’s affairs as at 28 February 2026 and of the group’s incoming resources and application of resources, including its income and expenditure, for the year then ended;
have been properly prepared in accordance with United Kingdom Generally Accepted Accounting Practice;
have been prepared in accordance with the requirements of the Companies Act 2006 and the Charities Act 2011.

Basis for opinion

We conducted our audit in accordance with International Standards on Auditing (UK) ("ISAs (UK)") and applicable law. Our responsibilities under those standards are further described in the auditors' responsibilities for the audit of the financial statements section of our report. We are independent of the charitable company in accordance with the ethical requirements that are relevant to our audit of the financial statements in the UK, including the FRC’s Ethical Standard, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Conclusions relating to going concern

In auditing the financial statements, we have concluded that the trustees’ use of the going concern basis of accounting in the preparation of the financial statements is appropriate.

Based on the work we have performed, we have not identified any material uncertainties relating to events or conditions that, individually or collectively, may cast significant doubt on the charitable company's ability to continue as a going concern for a period of at least twelve months from when the financial statements are authorised for issue.

Our responsibilities and the responsibilities of the trustees with respect to going concern are described in the relevant sections of this report.

Other information

The other information comprises the information included in the annual report, other than the financial statements and our auditors' report thereon. The trustees are responsible for the other information. Our opinion on the financial statements does not cover the other information and, except to the extent otherwise explicitly stated in our report, we do not express any form of assurance conclusion thereon.

In connection with our audit of the financial statements, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the audit or otherwise appears to be materially misstated. If we identify such material inconsistencies or apparent material misstatements, we are required to determine whether there is a material misstatement in the financial statements or a material misstatement of the other information. If, based on the work we have performed, we conclude that there is a material misstatement of this other information; we are required to report that fact.

We have nothing to report in this regard.

Docusign Envelope ID: 6BC1C99D-70B1-8F25-81A3-6EF0709C47F2 Hyperlipidaemia Education & Atherosclerosis Research Trust UK (trading as HEART UK) (A company limited by guarantee)

Independent Auditors' Report to the trustees of HEART UK

Opinion on other matters prescribed by the Companies Act 2006

In our opinion, based on the work undertaken in the course of the audit:

the information given in the trustees’ annual report for the financial year for which the financial statements are prepared is consistent with the financial statements; and
the trustees’ annual report have been prepared in accordance with applicable legal requirements.

Matters on which we are required to report by exception

In the light of the knowledge and understanding of the group and parent charitable company and its environment obtained in the course of the audit, we have not identified material misstatements in the trustees’ annual report.

We have nothing to report in respect of the following matters where the Companies Act 2006 and the Charities Act 2011 require us to report to you if, in our opinion:

the parent charitable company has not kept adequate and sufficient accounting records, or returns adequate for our audit have not been received from branches not visited by us; or
the parent charitable company’s financial statements are not in agreement with the accounting records and returns; or
certain disclosures of trustees’ remuneration specified by law are not made; or
we have not received all the information and explanations we require for our audit.
the trustees were not entitled to prepare the financial statements in accordance with the small companies regime and take advantage of the small companies exemption in preparing the Trustees’ Annual Report and from preparing a strategic report.

Responsibilities of trustees

As explained more fully in the statement of trustees’ responsibilities set out on page 17, the trustees (who are also the directors of the charitable company for the purposes of company law) are responsible for the preparation of the financial statements and for being satisfied that they give a true and fair view, and for such internal control as the trustees determine is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, the trustees are responsible for assessing the group and parent charitable company’s ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the trustees either intend to liquidate the group or parent charitable company or to cease operations, or have no realistic alternative but to do so.

Auditors' responsibilities for the audit of the financial statements

We have been appointed as auditor under the Companies Act 2006 and section 151 of the Charities Act 2011 and report in accordance with those Acts.

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditors' report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with ISAs (UK) will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

Irregularities, including fraud, are instances of non-compliance with laws and regulations. We design procedures in line with our responsibilities, outlined above, to detect material misstatements in respect of irregularities, including fraud. The extent to which our procedures are capable of detecting irregularities,

Docusign Envelope ID: 6BC1C99D-70B1-8F25-81A3-6EF0709C47F2

Hyperlipidaemia Education & Atherosclerosis Research Trust UK (trading as HEART UK) (A company limited by guarantee)

Independent Auditors' Report to the trustees of HEART UK

Auditors' responsibilities for the audit of the financial statements (continued)

Explanation as to what extent the audit was considered capable of detecting irregularities, including fraud

The objectives of our audit in respect of fraud, are; to identify and assess the risks of material misstatement of the financial statements due to fraud; to obtain sufficient appropriate audit evidence regarding the assessed risks of material misstatement due to fraud, through designing and implementing appropriate responses to those assessed risks; and to respond appropriately to instances of fraud or suspected fraud identified during the audit. However, the primary responsibility for the prevention and detection of fraud rests with both management and those charged with governance of the charitable company.

Our approach was as follows:

We obtained an understanding of the legal and regulatory requirements applicable to the charitable company and considered that the most significant are the Companies Act 2006, the Charities Act 2011, the Charity SORP, and UK financial reporting standards as issued by the Financial Reporting Council
We obtained an understanding of how the charitable company complies with these requirements by discussions with management and those charged with governance.
We assessed the risk of material misstatement of the financial statements, including the risk of material misstatement due to fraud and how it might occur, by holding discussions with management and those charged with governance.
We inquired of management and those charged with governance as to any known instances of noncompliance or suspected non-compliance with laws and regulations.
Based on this understanding, we designed specific appropriate audit procedures to identify instances of noncompliance with laws and regulations. This included making enquiries of management and those charged with governance and obtaining additional corroborative evidence as required.

As part of an audit in accordance with ISAs (UK) we exercise professional judgement and maintain professional scepticism throughout the audit. We also:

Identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purposes of expressing an opinion on the effectiveness of the group and parent charitable company’s internal control.
Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the trustees.
Conclude on the appropriateness of the trustees’ use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the group and parent charitable company’s ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor’s report to the related disclosures in the financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor’s report. However, future events or conditions may cause the group or parent charitable company to cease to continue as a going concern.

Docusign Envelope ID: 6BC1C99D-70B1-8F25-81A3-6EF0709C47F2

Hyperlipidaemia Education & Atherosclerosis Research Trust UK (trading as HEART UK) (A company limited by guarantee)

Independent Auditors' Report to the trustees of HEART UK

Auditors' responsibilities for the audit of the financial statements (continued)

Evaluate the overall presentation, structure and content of the financial statements, including the disclosures, and whether the financial statements represent the underlying transactions and events in a manner that achieves fair presentation.
Obtain sufficient appropriate audit evidence regarding the financial information of the entities or business activities within the group to express an opinion on the consolidated financial statements. We are responsible for the direction, supervision and performance of the group audit. We remain solely responsible for our audit report.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

Use of this report

This report is made solely to the charitable company’s members, as a body, in accordance with Chapter 3 of Part 16 of the Companies Act 2006 and, in respect of the consolidated financial statements, to the charity’s trustees, as a body, in accordance with Chapter 3 of Part 8 of the Charities Act 2011. Our audit work has been undertaken so that we might state to the charitable company’s members and trustees those matters which we are required to state to them in an auditor’s report and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to any party other than the charitable company, the charitable company’s members, as a body, and the charity’s trustees, as a body, for our audit work, for this report, or for the opinion we have formed.

Luke Holt (Senior Statutory Auditor) 6th Floor, 9 Appold Street for and on behalf of Moore Kingston Smith LLP London EC2A 2AP

Date: 19/8/2026

Docusign Envelope ID: 6BC1C99D-70B1-8F25-81A3-6EF0709C47F2 Hyperlipidaemia Education & Atherosclerosis Research Trust UK (trading as HEART UK) (A company limited by guarantee)

Consolidated Statement of Financial Activities (incorporating income and expenditure account) for the year ended 28 February 2026

Note Income from: Donations, legacies and grants 2 Charitable activities 3 Trading income 4 Other income 5 Investment income 6 Total income Expenditure on: Raising funds: Fundraising 7 Expenditure from trading 8 Charitable activities 9 Total expenditure Net (expenditure) / income Net gain on investments 15 Net movement in funds Reconciliation of funds: Total funds brought forward Total funds carried forward	Unrestricted funds 2026 £ 609,856 361,430 719,488 89,269 6,623 1,786,666 192,992 571,707 754,793 1,519,492 267,174 (2,307) 264,867 590,176 855,043	Restricted funds 2026 £ 108,241 - - - 108,241 - - 56,169 56,169 52,072 - 52,072 53,843 105,915	Total funds 2026 Total funds 2025 £ £ 718,097 432,659 361,430 290,619 719,488 756,156 89,269 88,569 6,623 9,001 1,894,907 1,577,004 192,992 182,150 571,707 536,980 810,962 773,917 1,575,661 1,493,047 319,246 83,957 (2,307) 2,706 316,939 86,663 644,019 557,356 960,958 644,019

The notes on pages 25 to 39 form part of these financial statements.

All amounts are derived from continuing activities. All gains and losses recognised in the year are included above.

Docusign Envelope ID: 6BC1C99D-70B1-8F25-81A3-6EF0709C47F2

Hyperlipidaemia Education & Atherosclerosis Research Trust UK (trading as HEART UK) (A company limited by guarantee)

Consolidated Balance Sheet as at 28 February 2026

Note Fixed assets Intangible assets 13 Tangible assets 14 Investments 15 Current assets Debtors:Amounts receivable within one year 16 Cash at bank and in hand Current asset investments Debtors:Amounts receivable after one year Creditors:amounts falling due within one year 17 Net current assets Net assets Charity Funds Restricted funds 18 Unrestricted funds 18 Total funds	£ 336,398 761,170 93,558 1,191,126 (362,468)	2026 £ 11,394 5,226 115,680 132,300 - 828,658 960,958 105,915 855,043 960,958	£ 415,578 628,368 0 1,043,946 (478,758)	2025 £ 874 9,969 67,988
				78,831 - 565,188
				644,019
				53,843 590,176
				644,019

As permitted by s408 Companies Act 2006, the company has not presented its own income and expenditure statement and related notes. The company's surplus for the year was £322,849 (2025 surplus £86,663 ).

The charity's financial statements have been prepared in accordance with the provisions applicable to companies subject to the small companies regime.

18/8/2026

The financial statements were approved and authorised for issue by the trustees on and signed on their behalf, by:

Mr P Green, Chairman Mr N R Phipps ACA, Trustee

The notes on pages 25 to 39 form part of these financial statements.

Docusign Envelope ID: 6BC1C99D-70B1-8F25-81A3-6EF0709C47F2

Hyperlipidaemia Education & Atherosclerosis Research Trust UK (trading as HEART UK) (A company limited by guarantee)

Charity balance sheet as at 28 February 2026

Note Fixed assets Intangible assets 13 Tangible assets 14 Investments 15 Current assets Debtors 16 Cash at bank and in hand	£ 214,331 597,905	2026 £ 394 5,226 115,682 121,302	£ 217,468 518,904	2025 £ 874 9,969 67,990
				78,833
Current asset investments	93,558		0 736,372
	905,794
Debtors:Amounts receivable after one year Creditors:amounts falling due within one year 17 Net current assets Net assets Charity Funds Restricted funds 18 Unrestricted funds 18 Total funds	(66,138)	- 839,656 960,958 162,084 798,874 960,958	(171,186)	- 565,186
				644,019
				53,843 590,176
				644,019

The charity's financial statements have been prepared in accordance with the provisions applicable to companies subject to the small companies regime.

18/8/2026

The financial statements were approved and authorised for issue by the trustees on and signed on their behalf, by:

Mr P Green, Chairman Mr N R Phipps ACA, Trustee

The notes on pages 25 to 39 form part of these financial statements.

Docusign Envelope ID: 6BC1C99D-70B1-8F25-81A3-6EF0709C47F2 Hyperlipidaemia Education & Atherosclerosis Research Trust UK (trading as HEART UK) (A company limited by guarantee)

Consolidated Statement of Cash Flows for the year ended 28 February 2026

Note Cash flows from operating activities Net cash (used in)/provided by operating activities 20 Cash flows from investing activities: Purchase of intangible fixed assets 13 Purchase of tangible fixed assets 14 Purchase of listed investments 15 Disposal of listed investments 15 Investment income Net cash used in investing activities Change in cash and cash equivalents in the year Cash and cash equivalents brought forward Cash and cash equivalents carried forward 21	2026 £ 283,006 (11,000) (2,270) (49,999) - 6,623 (56,646) 226,360 628,368 854,728	2025 £ (42,954)
		- (2,051) - - 9,001
		6,950
		(36,004) 664,372
		628,368

The notes on pages 26 to 39 form part of these financial statements.

Analysis of consolidated net resources

	At 1 March 2025	At 28 February 2026
	£	£
Cash at bank and in hand	628,368	761,170
Current asset investments	0 628,368	93,558 854,728

Docusign Envelope ID: 6BC1C99D-70B1-8F25-81A3-6EF0709C47F2

Hyperlipidaemia Education & Atherosclerosis Research Trust UK (trading as HEART UK) (A company limited by guarantee)

Notes to the financial statements for the year ended 28 February 2026

1. Accounting policies

1.1 Basis of preparation of financial statements

The financial statements have been prepared under the historical cost convention as modified by the revaluation of investments to market value and in compliance with Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their financial statements in accordance with the Financial Reporting Standard 102 including Update Bulletin 2, "The Financial Reporting Standard applicable in the United Kingdom and the Republic of Ireland" ("FRS 102") and the Charities Act 2011.

Hyperlipidaemia Education & Atherosclerosis Research Trust UK (HEART UK) is a company limited by guarantee and a registered charity and incorporated in England and Wales. HEART UK meets the definition of a public benefit entity under FRS 102.

The financial statements are prepared in sterling which is the functional currency of the Group. Monetary amounts in these financial statements are rounded to the nearest pound.

The Statement of financial activities (SOFA) and Balance sheet consolidate the financial statements of the charity and its subsidiary undertaking. The results of the subsidiary are consolidated on a line by line basis and the detailed results are disclosed in note 24 of the financial statements.

1.2 Going concern

The trustees have assessed whether the use of the going concern basis is appropriate and have considered possible events or conditions that might cast significant doubt on the ability of the company to continue as a going concern. The trustees have made this assessment for a period of at least one year from the date of approval of the financial statements. In particular the trustees have considered the company's forecasts and projections and have taken account of the Coronavirus pandemic. The company had adequate resources to continue in operation for at least twelve months from the approval of the financial statements. The company therefore continues to adopt the going concern basis in preparing its financial statements.

1.3 Fund accounting

General funds are unrestricted funds which are available for use at the discretion of the trustees in furtherance of the general objectives of the charity and which have not been designated for other purposes.

Restricted funds are funds which are to be used in accordance with specific restrictions imposed by donors or which have been raised by the charity for particular purposes. The costs of raising and administering such funds are charged against the specific fund. The aim and use of each restricted fund is set out in the notes to the financial statements.

Those funds which are not restricted income funds, are unrestricted income funds which are sub analysed between designated funds, where trustees have set aside amounts to be used for specific purposes or which reflect the non-binding wishes of donors; and unrestricted funds, which are used at the trustees' discretion in furtherance of the general objectives of HEART UK.

Docusign Envelope ID: 6BC1C99D-70B1-8F25-81A3-6EF0709C47F2

Hyperlipidaemia Education & Atherosclerosis Research Trust UK (trading as HEART UK) (A company limited by guarantee)

Notes to the financial statements for the year ended 28 February 2026

1. Accounting policies (continued)

1.4 Income

All income is recognised once the charity has entitlement to the income, it is probable that the income will be received and the amount of income receivable can be measured reliably.

For legacies, entitlement is taken as the earlier of the date on which either: the charity is aware that probate has been granted, the estate has been finalised and notification has been made by the executor(s) to the Trust that a distribution will be made, or when a distribution is received from the estate. Receipt of a legacy, in whole or in part, is only considered probable when the amount can be measured reliably and the charity has been notified of the executor's intention to make a distribution. Where legacies have been notified to the charity, or the charity is aware of the granting of probate, and the criteria for income recognition have not been met, then the legacy is treated as a contingent asset and disclosed if material.

Donated services or facilities are recognised when the charity has control over the item, any conditions associated with the donated item have been met, the receipt of economic benefit from the use of the charity of the item is probable and that economic benefit can be measured reliably. Donated services are valued at the amount HEART UK would be prepared to pay for a similar service.

Interest on funds held on deposit is included when receivable and the amount can be measured reliably by the charity; this is normally upon notification of the interest paid or payable by the bank.

Income tax recoverable in relation to donations received under Gift Aid or deeds of covenant is recognised at the time of the donation.

Trading income represents turnover in the trading subsidiary which consists of conference sponsorships, delegate income, product licence fees and other services and are accounted net of any discounts and exclusive of value added tax.

1.5 Expenditure

Expenditure is recognised once there is a legal or constructive obligation to transfer economic benefit to a third party, it is probable that a transfer of economic benefits will be required in settlement and the amount of the obligation can be measured reliably. Expenditure is classified by activity. The costs of each activity are made up of the total of direct costs and shared costs, including support costs involved in undertaking each activity. Direct costs attributable to a single activity are allocated directly to that activity. Shared costs which contribute to more than one activity and support costs which are not attributable to a single activity are apportioned between those activities on a basis consistent with the use of resources. Central staff costs are allocated on the basis of time spent, and depreciation charges allocated on the portion of the asset’s use.

Costs of generating funds are costs incurred in attracting voluntary income, and those incurred in trading activities that raise funds.

Charitable activities are costs incurred on the charity's educational operations, including support costs apportioned to charitable activities.

1.6 Operating leases

Leases that do not transfer all the risks and rewards of ownership are classified as operating leases. Payments under operating leases are charged to the SOFA on a straight line basis over the period of the lease. Incentives received to enter into operating leases are credited to the SOFA to reduce the lease expense, on a straight line basis over the period of the lease.

Docusign Envelope ID: 6BC1C99D-70B1-8F25-81A3-6EF0709C47F2

Hyperlipidaemia Education & Atherosclerosis Research Trust UK (trading as HEART UK) (A company limited by guarantee)

Notes to the financial statements for the year ended 28 February 2026

1. Accounting policies (continued)

1.7 Employee benefits

The charity operates a defined contribution pension and death in service scheme. The pension charge represents the amounts payable by the charity to the fund in respect of the year.

1.8 Intangible fixed assets and amortisation

Intangible assets are capitalised and recognised when future economic benefits are probable and the cost or value of the asset can be measured reliably. Intangible assets are initially recognised at cost and are subsequently measured at cost net of amortisation and any provision for impairment. Intangible assets are capitlised where the purchase price exceeds £500.

Amortisation is provided on intangible fixed assets at rates calculated to write off the cost of each asset, less their estimated residual value, over their expected useful lives on the following bases:

Website development

20% straight line

1.9 Tangible fixed assets and depreciation

Tangible fixed assets are carried at cost, net of depreciation and any provision for impairment. Depreciation is provided at rates calculated to write off the cost of fixed assets, less their estimated residual value, over their expected useful lives on the following bases:

Tangible assets are capitlised where the purchase price exceeds £500.

Office equipment 15% straight line - Computer equipment 33% straight line

1.10 Fixed asset investments

Fixed asset investments are a form of financial instrument and are initially recognised at their transaction cost and subsequently measured at fair value at the balance sheet date, unless fair value cannot be measured reliably in which case it is measured at cost less impairment. Investment gains and losses, whether realised or unrealised, are combined and shown in the heading ‘Net gains/(losses) on investments’ in the Statement of financial activities. The investment in subsidiary is value at cost.

1.11 Debtors

Trade and other debtors are recognised at the settlement amount after any trade discount offered.

1.12 Cash at bank and in hand

Cash at bank and in hand includes cash and short term highly liquid investments with a short maturity of three months or less from the date of acquisition or opening of the deposit or similar account.

Docusign Envelope ID: 6BC1C99D-70B1-8F25-81A3-6EF0709C47F2

Hyperlipidaemia Education & Atherosclerosis Research Trust UK (trading as HEART UK) (A company limited by guarantee)

Notes to the financial statements for the year ended 28 February 2026

1. Accounting policies (continued)

1.13 Financial instruments

The charity only has financial assets and financial liabilities of a kind that qualify as basic financial instruments. Basic financial instruments are initially recognised at transaction value and subsequently measured at their settlement value with the exception of bank loans which are subsequently measured at amortised cost using the effective interest method.

1.14 Critical accounting judgements and estimation uncertainty

Estimates and judgments are continually evaluated and are based on historical experience and other factors, including expectations of future events that are believed to be reasonable under the circumstances.

Significant accounting judgements and estimates include:

Legacy accrued income
Depreciation and amortisation rates
CVD Accrued income

a. Useful economic lives of tangible and intangible assets

The annual depreciation and amortisation charge for fixed assets is sensitive to changes in the estimated useful economic lives of the assets. The useful economic lives are re-assessed annually. These are amended where necessary to reflect current estimates, based on technological advancement, future investments, economic utilisation and the physical condition of the assets. See notes 13 and 14 for the carrying value of assets and note 1.7 and 1.8 for the useful economic lives.

Docusign Envelope ID: 6BC1C99D-70B1-8F25-81A3-6EF0709C47F2 Hyperlipidaemia Education & Atherosclerosis Research Trust UK (trading as HEART UK) (A company limited by guarantee)

Notes to the financial statements for the year ended 28 February 2026

2 Income from donations, legacies and grants

Donations Legacies Gift aid Grants Total donations and legacies Total 2025	Unrestricted funds 2026 £ 71,916 489,742 28,198 20,000 609,856 328,535	Restricted funds 2026 £ - - - 108,241 108,241 104,124	Total funds 2026 £ 71,916 489,742 28,198 128,241 718,097 432,659	Total funds 2025 £ 172,402 237,997 22,260 -
				432,659

The estimated value of legacies notified but neither received nor accrued income (as they do not meet the Sorp recognition criteria) as at 28 February 2026 is £nil (2025: £250,000).

3 Charitable activities

Unrestricted funds 2026 £ Fundraising 361,430 361,430 Total 2025 290,619 Trading income Unrestricted funds 2026 £ Income from trading subsidiary 719,488 Please see note 24 for details of the trading subsidiary	Restricted funds 2026 £ - - - Restricted funds 2026 £ - income.	Total funds 2026 £ 361,430 361,430 290,619 Total funds 2026 £ 719,488	Total funds 2025 £ 290,619
			290,619
			Total funds 2025 £ 756,156

4 Trading income

Docusign Envelope ID: 6BC1C99D-70B1-8F25-81A3-6EF0709C47F2 Hyperlipidaemia Education & Atherosclerosis Research Trust UK (trading as HEART UK) (A company limited by guarantee)

Notes to the financial statements for the year ended 28 February 2026

5 Other income

Other income Total 2025	Unrestricted funds 2026 £ 89,269 88,569	Restricted funds 2026 £ - -	Total funds Total funds 2026 2025 £ £ 89,269 88,569 88,569

6 Investment income

Dividend receivable Interest receivable Total 2025 Raising funds Staff costs Other fundraising costs Total Total 2025	Unrestricted funds 2026 £ - 6,623 6,623 9,001 Unrestricted funds 2026 £ 139,419 53,573 192,992 182,150	Restricted funds 2026 £ - - - - Restricted funds 2026 £ - - - -	Total funds 2026 £ - 6,623 6,623 9,001 Total funds 2026 £ 139,419 53,573 192,992 182,150	Total funds 2025 £ - 9,001
				9,001
				Total funds 2025 £ 127,443 54,707
				182,150

7 Raising funds

Docusign Envelope ID: 6BC1C99D-70B1-8F25-81A3-6EF0709C47F2

Hyperlipidaemia Education & Atherosclerosis Research Trust UK (trading as HEART UK) (A company limited by guarantee)

Notes to the financial statements for the year ended 28 February 2026

8 9	Trading costs Direct costs Administrative Total Charitable activities	Unrestricted funds 2026 £ 451,568 120,139 571,707 Unrestricted funds 2026 £	Restricted funds 2026 £ - - - Restricted funds 2026 £	Total funds 2026 £ 451,568 120,139 571,707 Total funds 2026 £	Total funds 2025 £ 443,618 93,362
					536,980
					Total funds 2025 £
	Awareness, education and patient support	725,206	56,169	781,375	733,408
10 11	Governance costs (note 10) Governance costs Audit and accountancy fees Net movement in funds This is stated after charging: Depreciation of tangible fixed assets: Amortisation of intangible fixed assets	29,587 754,793 Unrestricted funds 2026 £ 29,587	- 56,169 Restricted funds 2026 £ -	29,587 810,962 Total funds 2026 £ 29,587 2026 £ 7,013 480	40,510
					773,918
					Total funds 2025 £ 40,510
					2025 £ 6,657 662
	Auditor's remuneration - audit Auditor's remuneration - non audit services			16,240 4,210	15,730 5,120

Docusign Envelope ID: 6BC1C99D-70B1-8F25-81A3-6EF0709C47F2 Hyperlipidaemia Education & Atherosclerosis Research Trust UK (trading as HEART UK) (A company limited by guarantee)

Notes to the financial statements for the year ended 28 February 2026

12 Staff costs

Wages and salaries Social security costs Other pension costs	2026 2025 £ £ 370,139 354,794 39,297 32,977 22,777 21,063 432,213 408,834

The average number of employees during the year was 9 (2025: 6)

The average number of full-time equivalent employees (including casual and part time staff) during the year was made up as follows:

	2026	2025
Charitable operations Management and central services	No. 3.8 3.5 7.3	No. 3.7 2.7
		6.4
The number of employees whose remuneration exceed £60,000, is shown below: 2026 No.		2025 No.
£60,000 to £69,999 £80,000 to £89,999 1		1 1

Key management personnel consists of the leadership management team and consists of 4 (2025: 3) individuals. Total remuneration to key management personnel totalled £253,814 in the year (2025: £241,856). During the year total travel expenses of £Nil (2025: £Nil) were reimbursed to no (2025: Nil) Trustees. During the year 5 trustees (2025: 3) donated a total of £1,116 (2025:£535).

13 Intangible fixed assets

Group and Charity Cost At 1 March 2025 Additions At 28 February 2026 Amortisation At 1 March 2025	£ 57,893 11,000 Website development
	68,893
	57,019
Charge for the year	480
Eliminated on disposals At 28 February 2026 Carrying amount At 28 February 2026 At 29 February 2025	-
	57,499
	11,394
	874

Docusign Envelope ID: 6BC1C99D-70B1-8F25-81A3-6EF0709C47F2

Hyperlipidaemia Education & Atherosclerosis Research Trust UK (trading as HEART UK) (A company limited by guarantee)

Notes to the financial statements for the year ended 28 February 2026

14 Tangible fixed assets

14	Tangible fixed assets
			£ £ 32,252 405 2,270 - (405) 34,522 0 22,283 405 7,013 - (405) 29,296 0 Office equipment Computer equipment		Total
	Group and Charity Cost At 1 March 2025 Additions Disposals At 28 February 2026 Depreciation At 1 March 2025 Charge for the year Eliminated on disposal At 28 February 2026				£ 32,657 2,270
					34,927
					22,688 7,013 (405)
					29,296
15	Carrying amount At 28 February 2026 At 29 February 2025 Fixed asset investments	5,226 9,969 2026 2025 Group		- 5,226 - 9,969 2026 2025 Charity	5,226
					9,969
		£	£	£	£
	Investments at market value Investment in subsidiary at cost	115,680 - 115,680	67,988 - 67,988	115,680 2 115,682	67,988 2
					67,990

				2026	2025
	Market value			£	£
	At 1 March 2025 Additions Disposals Net gains/( losses) At 28 February 2026			67,988 49,999 - (2,307) 115,680	65,282 - - 2,706
					67,988
	Historical cost of listed investments			50,000	50,000

Docusign Envelope ID: 6BC1C99D-70B1-8F25-81A3-6EF0709C47F2

Hyperlipidaemia Education & Atherosclerosis Research Trust UK (trading as HEART UK) (A company limited by guarantee)

Notes to the financial statements for the year ended 28 February 2026

15 Fixed asset investments (continued)

15	Fixed asset investments (continued)	Fixed asset investments (continued)	Fixed asset investments (continued)
	Significant investment holdings based on market value at 28 February			2026 were:
				Historical costs		Market
				(£)		value (£)
	COIF Charities Investment Fund				50,000	115,680
					50,000	115,680
16	Debtors
			Group			Charity
		2026	2025		2026	2025
		£	£		£	£
	Trade debtors	103,032	187,726		1,355	-
	Amounts owed by group undertakings	-	-		3,089	-
	Other debtors	-	-		-	-
	Prepayments and accrued income	233,366	227,852	209	209,887	217,468
	Amounts due over 1 year
	Prepayments and accrued income	-	-		-	-
		336,398	415,578		214,331	217,468
17	Creditors: Amounts falling due within one year
			Group			Charity
		2026	2025		2026	2025
		£	£		£	£
	Trade creditors	55,364	95,648		33,563	58,621
	Amounts owed to group undertakings	-	-		-	69,906
	Other taxation and social security	19,430	42,214		11,240	9,620
	Other creditors	589	11,500		59	11,500
	Accruals and deferred income	287,085	329,396		21,276	21,539
		362,468	478,758		66,138	171,186
	Deferred income in the charity relates to income to support for future events			and are included in creditors at the
	period end. Deferred income on a group basis includes sponsorship and licence income earned in the
	subsequent financial year.
	Group deferred income	Brought	Amount	Amount		Carried
		forward	added	released		forward
		£	£		£	£
	Deferred income 2026	278,642	196,050		(278,642)	196,050
	Deferred income 2025	238,157	278,642	(238,157)		278,642

Docusign Envelope ID: 6BC1C99D-70B1-8F25-81A3-6EF0709C47F2

Hyperlipidaemia Education & Atherosclerosis Research Trust UK (trading as HEART UK) (A company limited by guarantee)

Notes to the financial statements for the year ended 28 February 2026

18 Statement of funds

a. Group General funds General funds - all funds Total unrestricted funds Restricted funds	Balance at 1 March 2025 £ 590,176 590,176	Income £ 1,786,666	Expenditure £ (1,519,492) (1,519,492)	Net gains and transfers £ (2,307) (2,307)	Balance at 28 February 2026 £ 855,043
		1,786,666			855,043

Restricted funds - all funds	53,843	108,241	(56,169)	-	105,915
Total of funds a. Charity General funds General funds - all funds Total unrestricted funds Restricted funds Restricted funds - all funds Total of funds	644,019 Balance at 1 March 2025 £ 590,176 590,176 53,843 644,019	1,894,907 Income £ 1,214,959	(1,575,661) Expenditure £ (1,003,954) (1,003,954) - (1,003,954)	- 2,307 Net gains and transfers £ (2,307) (2,307) - (2,307)	960,958
					Balance at 28 February 2026 £ 798,874
		1,214,959 108,241 1,323,200			798,874
					162,084
					960,958

Docusign Envelope ID: 6BC1C99D-70B1-8F25-81A3-6EF0709C47F2

Hyperlipidaemia Education & Atherosclerosis Research Trust UK (trading as HEART UK) (A company limited by guarantee)

Notes to the financial statements for the year ended 28 February 2026

19 Analysis of net assets between funds

Group Intangible fixed assets Tangible fixed assets Fixed asset investments Current assets Creditors due within one year Charity Intangible fixed assets Tangible fixed assets Fixed asset investments Current assets Creditors due within one year	Unrestricted funds 2026 £ 11,394 5,226 115,680 1,085,211 (362,468) 855,043 Unrestricted funds 2026 £ 394 5,226 115,682 743,710 (66,138) 798,874	Restricted funds 2026 £ - - - 105,915 - 105,915 Restricted funds 2026 £ - - - 162,084 - 162,084	Total funds 2026 £ 11,394 5,226 115,680 1,191,126 (362,468)
			960,958
			Total funds 2026 £ 394 5,226 115,682 905,794 (66,138)
			960,958

20 Reconciliation of net movement in funds to net cash flow from operating activities

		Group
	2026	2025
	£	£
Adjustment for: Depreciation charges Amortisation charges Net (gains)/losses Investment Income Decrease in debtors Net cash (used in)/provide by operating activities increase in creditors Net (deficit)/income for the year (as per Statement of Financial Activities)	316,939 7,013 480 2,307 (6,623) 79,180 (116,290) 283,006	86,663 6,657 662 (2,706) (9,001) (170,090) 44,861
		(42,954)

Docusign Envelope ID: 6BC1C99D-70B1-8F25-81A3-6EF0709C47F2

Hyperlipidaemia Education & Atherosclerosis Research Trust UK (trading as HEART UK) (A company limited by guarantee)

Notes to the financial statements for the year ended 28 February 2026

21 Analysis of cash and cash equivalents

21 Analysis of cash and cash equivalents
		Group
	2026	2025
	£	£
Current asset investments Total Cash in hand	761,170 93,558 854,728	628,368 0
		628,368

22 Pension commitments

The group operates a defined contributions pension scheme. The pension cost charge in the year represents contributions payable by the group and amounted to £ 22,776(2025: £21,063).

23 Operating lease commitments

At 28 February 2026 the total future minimum lease payments under non-cancellable operating leases

Group and Charity Within 1 year Between 1 and 5 years Total	2026 2025 £ £ - - - - - -

Docusign Envelope ID: 6BC1C99D-70B1-8F25-81A3-6EF0709C47F2

Hyperlipidaemia Education & Atherosclerosis Research Trust UK (trading as HEART UK) (A company limited by guarantee)

Notes to the financial statements for the year ended 28 February 2026

24 Related party transactions

Some of the trustees hold positions within organisations with which HEART UK has links. Some of those organisations may make donations to, or seek product approval licenses from the charity or its trading subsidiary. The charity has a conflict of interest policy in place to ensure that potential conflicts are identified and dealt with appropriately. For the current and preceding year all transactions with these related parties are considered within the scope of normal transactions.

An income distribution was made from HEART UK Trading Company Limited, a wholly owned subsidiary, to HEART UK of £147,781 (2025: £219,176) being a distribution of 100% of their net profit in the year. At the year end an amount of £3,089 (2025: £69,906) was owed to the subsidiary.

25 Principal subsidiary

HEART UK has one wholly owned subsidiary, HEART UK Trading Company Limited, which acts as the trading subsidiary of the group and has been included in this set of consolidated financial statements. The company has entered into a deed of covenant to donate its distributable profits to HEART UK. The registered office of the subsidiary is 7 North Road, Maidenhead, Berkshire, SL6 1PE and its company number is 03679100. A summary of its trading results are shown below. A set of audited financial statements for this subsidiary are filed annually with the Registrar of Companies.

HEART UK Trading Company Limited results

Profit and loss Turnover Cost of Sales Administrative Expenses Operating profit Reconciliation of profit and loss reserves Brought forward Operating profit Distribution to HEART UK Carried forward	2026 2025 £ £ 719,488 756,156 (451,568) (442,896) (120,139) (94,084) 147,781 219,176 - - 147,781 219,176 (147,781) (219,176) - -

No charge to taxation will arise as the subsidiary company has entered into a deed of covenant to donate its distributable profits to its charitable parent HEART UK.

Docusign Envelope ID: 6BC1C99D-70B1-8F25-81A3-6EF0709C47F2

Hyperlipidaemia Education & Atherosclerosis Research Trust UK (trading as HEART UK) (A company limited by guarantee)

Notes to the financial statements for the year ended 28 February 2026

25 Principal subsidiary (continued)

Balance Sheet: Fixed assets	£ £ £ 2026 2025	£ £ £ 2026 2025	£
Intangible assets		11,000	-
Current assets Debtors Cash at bank and in hand Creditors:amounts falling due within one year Net current assets Net assets Capital and reserves Called up share capital Total Equity	122,067 163,265 285,332 (296,330)	268,016 109,464 377,480 (377,478) - 10,998 2 2 2	2

			2
			2
			2

The share capital represents 2 Ordinary shares of £1 each held by HEART UK.

26 Limited liability

HEART UK is a company limited by guarantee and as such does not have share capital. In the event of winding up the liability of each member is limited to £1.

2026-02-28-accounts

Hyperlipidaemia Education & Atherosclerosis Research Trust UK

Hyperlipidaemia Education & Atherosclerosis Research Trust UK (trading as HEART UK) (A company limited by guarantee)

Trustees

Registered office

Company secretary & Chief executive officer

Independent auditors

Our Impact in 2025-2026

Public Awareness and Support

784

146,274

2.5m

Healthcare Professionals

HEART UK – actively supported by gifts in wills and donations

National Level Impact

y - Our Key ges Public Affairs and Advocac Messa

NHS 10 Year Plan: Cardiovascular Disease (CVD) Modern Service Framework (MSF)

The Breadth of Our Advocacy work

Publications and Data

HEART UK – actively supported by gifts in wills and donations

Annual report incorporating a Directors’ Report and Accounts for the year ended 28 February 2026

OBJECTIVES AND ACTIVITIES

Introduction

Aims and objectives

Volunteers

Public Benefit

Diversity, equality and inclusion

Our Values

Environment, Social and Governance

The Charity Governance Code

ACHIEVEMENTS AND PERFORMANCE

Background information

The team

Providing scientifically based, factually accurate information

The HEART UK Helpline

Healthcare professional support

Lipid Intelligence Network

Lipid Interest Group

Other networks

Annual scientific conference

Nutrition Academy

Major Achievements

ChangeMaker Programme

Policy and public affairs

Cholesterol SMART

Awareness raising

PRINCIPLE FUNDING

RISK MANAGEMENT

FINANCIAL REVIEW

INVESTMENT POLICY

RESERVES POLICY

PLANS FOR THE FUTURE

STRUCTURE, GOVERNANCE AND MANAGEMENT

Committees

Finance and Risk

Income, Communications and Services

Medical and Scientific Research Committee (MS&R)

The Healthcare Committee

Policy and Public Affairs Committee

Board Nomination Committee

Task and finish groups

Lipoprotein Apheresis

Conference organising

Research Grant Scheme

Policy Development

Product Approval

Cardiovascular Disease Collaborative

ChangeMaker

Community Service Volunteers

The Simon Broome Steering Committee

STAFF

PAY AND REMUNERATION

AUDITOR

TRUSTEE APPOINTMENT, INDUCTION AND TRAINING

SMALL COMPANIES REGIME

CONSIDERATION OF GOING CONCERN

STATEMENT OF TRUSTEES’ RESPONSIBILITIES

AUDIT INFORMATION

AUDITORS

THANKS FROM THE CHAIR OF TRUSTEES